KR101561360B1 - 이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도 - Google Patents

이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도 Download PDF

Info

Publication number
KR101561360B1
KR101561360B1 KR1020137018235A KR20137018235A KR101561360B1 KR 101561360 B1 KR101561360 B1 KR 101561360B1 KR 1020137018235 A KR1020137018235 A KR 1020137018235A KR 20137018235 A KR20137018235 A KR 20137018235A KR 101561360 B1 KR101561360 B1 KR 101561360B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
imidazo
quinolin
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137018235A
Other languages
English (en)
Korean (ko)
Other versions
KR20130116302A (ko
Inventor
데이빗 앤쏘니 바르다
매리 마가레트 메이더
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20130116302A publication Critical patent/KR20130116302A/ko
Application granted granted Critical
Publication of KR101561360B1 publication Critical patent/KR101561360B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137018235A 2011-01-14 2012-01-11 이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도 Expired - Fee Related KR101561360B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14
US61/432,958 2011-01-14
PCT/US2012/020897 WO2012097039A1 (en) 2011-01-14 2012-01-11 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Publications (2)

Publication Number Publication Date
KR20130116302A KR20130116302A (ko) 2013-10-23
KR101561360B1 true KR101561360B1 (ko) 2015-10-16

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137018235A Expired - Fee Related KR101561360B1 (ko) 2011-01-14 2012-01-11 이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도

Country Status (39)

Country Link
US (2) US8440829B2 (https=)
EP (1) EP2663564B1 (https=)
JP (1) JP5891247B2 (https=)
KR (1) KR101561360B1 (https=)
CN (1) CN103282364B (https=)
AR (1) AR084551A1 (https=)
AU (1) AU2012205619B2 (https=)
BR (1) BR112013017672A2 (https=)
CA (1) CA2824760C (https=)
CL (1) CL2013002005A1 (https=)
CO (1) CO6731133A2 (https=)
CR (1) CR20130289A (https=)
CY (1) CY1116007T1 (https=)
DK (1) DK2663564T3 (https=)
DO (1) DOP2013000158A (https=)
EA (1) EA022163B1 (https=)
EC (1) ECSP13012764A (https=)
ES (1) ES2531891T3 (https=)
GT (1) GT201300180A (https=)
HR (1) HRP20150135T1 (https=)
HU (1) HUE024426T2 (https=)
IL (1) IL227165A (https=)
JO (1) JO3003B1 (https=)
ME (1) ME02019B (https=)
MX (1) MX2013008185A (https=)
MY (1) MY164705A (https=)
PE (1) PE20140864A1 (https=)
PH (1) PH12013501493A1 (https=)
PL (1) PL2663564T3 (https=)
PT (1) PT2663564E (https=)
RS (1) RS53828B1 (https=)
SG (1) SG191744A1 (https=)
SI (1) SI2663564T1 (https=)
SV (1) SV2013004496A (https=)
TN (1) TN2013000237A1 (https=)
TW (1) TWI518086B (https=)
UA (1) UA109921C2 (https=)
WO (1) WO2012097039A1 (https=)
ZA (1) ZA201304757B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
HK1254687A1 (zh) * 2015-12-15 2019-07-26 Eli Lilly And Company 用於癌症的联合疗法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017180385A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
ES2881801T3 (es) * 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
MA45025A (fr) 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
ES2974742T3 (es) * 2020-09-21 2024-07-01 Wei Zhong Compuestos de 1-(3,3-difluoropiperidin-4-il)-imidazo[4,5-c]quinolin-2-ona sustituidos con capacidad de penetración en la barrera hematoencefálica
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038165A1 (en) 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010139747A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
DE602004014969D1 (de) 2003-11-21 2008-08-21 Novartis Ag 1h-imidazochinolinderivate als proteinkinaseinhibitoren
CA2598656A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
NZ596487A (en) 2009-06-04 2012-11-30 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
AU2009349135A1 (en) * 2009-06-30 2012-02-16 Piramal Enterprises Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
JP2014504286A (ja) * 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038165A1 (en) 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010139747A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Also Published As

Publication number Publication date
KR20130116302A (ko) 2013-10-23
EA022163B1 (ru) 2015-11-30
ECSP13012764A (es) 2013-09-30
EP2663564A1 (en) 2013-11-20
SV2013004496A (es) 2017-11-07
CO6731133A2 (es) 2013-08-15
NZ611541A (en) 2015-02-27
AU2012205619A1 (en) 2013-06-27
DK2663564T3 (en) 2015-01-12
CL2013002005A1 (es) 2013-12-27
US8658668B2 (en) 2014-02-25
CY1116007T1 (el) 2017-01-25
CA2824760A1 (en) 2012-07-19
PH12013501493A1 (en) 2021-06-02
DOP2013000158A (es) 2013-11-30
EP2663564B1 (en) 2014-12-17
PT2663564E (pt) 2015-02-24
WO2012097039A1 (en) 2012-07-19
SI2663564T1 (sl) 2015-01-30
MY164705A (en) 2018-01-30
US20130237562A1 (en) 2013-09-12
ME02019B (me) 2015-05-20
MX2013008185A (es) 2013-08-21
ZA201304757B (en) 2014-12-23
HUE024426T2 (en) 2016-01-28
CR20130289A (es) 2013-10-07
SG191744A1 (en) 2013-08-30
TWI518086B (zh) 2016-01-21
PE20140864A1 (es) 2014-07-19
HK1188454A1 (en) 2014-05-02
IL227165A (en) 2016-06-30
TW201307343A (zh) 2013-02-16
CA2824760C (en) 2016-03-15
HRP20150135T1 (xx) 2015-03-13
GT201300180A (es) 2014-04-08
TN2013000237A1 (en) 2014-11-10
EA201390823A1 (ru) 2013-12-30
US20120184577A1 (en) 2012-07-19
CN103282364A (zh) 2013-09-04
PL2663564T3 (pl) 2015-05-29
JO3003B1 (ar) 2016-09-05
RS53828B1 (sr) 2015-06-30
US8440829B2 (en) 2013-05-14
CN103282364B (zh) 2015-06-17
ES2531891T3 (es) 2015-03-20
BR112013017672A2 (pt) 2018-09-18
AU2012205619B2 (en) 2015-05-21
AR084551A1 (es) 2013-05-22
UA109921C2 (uk) 2015-10-26
JP5891247B2 (ja) 2016-03-22
JP2014502638A (ja) 2014-02-03

Similar Documents

Publication Publication Date Title
KR101561360B1 (ko) 이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도
CA3144859C (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
AU2025260019A1 (en) Cyclin-dependent kinase 2 biomarkers and uses thereof
RU2326882C2 (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
CA3110502A1 (en) Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases
JP2009518340A (ja) ＥｐｈＢおよびＶＥＧＦＲ２キナーゼ阻害剤としてのピラゾロ［１，５−ａ］ピリジン−３−カルボン酸
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
US20230002376A1 (en) Bicyclic pyrazolyl amines as cdk2 inhibitors
AU2021204704B2 (en) Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
EP3661935B1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
ES2958528T3 (es) Macrociclos sustituidos útiles como inhibidores de quinasas
JP2013530250A (ja) 二環式ピリミジン化合物
WO2020077944A1 (zh) 嘌呤系列衍生物及其制备方法和用途
JP5886868B2 (ja) 置換ピリミド［１，２−ｂ］インダゾールおよびＰＩ３Ｋ／ＡＫＴ経路のモジュレーターとしてのそれらの使用
NZ611541B2 (en) Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor
HK1188454B (en) Imidazo [4, 5 -c]quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191013